In a randomized, double-blind, placebo-controlled study of 180 adults with knee osteoarthritis, Maxicuma demonstrated significant improvements in knee pain, stiffness, mobility and physical function compared with placebo, with benefits observed as early as 30 days.
In a randomized, double-blind, placebo-controlled study of 180 adults with knee osteoarthritis, Maxicuma demonstrated significant improvements in knee pain, stiffness, mobility and physical function compared with placebo, with benefits observed as early as 30 days.